Patent application number | Description | Published |
20100272822 | NANOCELL DRUG DELIVERY SYSTEM - Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antiangiogenic agent. | 10-28-2010 |
20100303912 | Nanocell Drug Delivery System - Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent. | 12-02-2010 |
20130171091 | Nanocell Drug Delivery System - Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent. | 07-04-2013 |
20130171205 | Nanocell Drug Delivery System - Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antiangiogenic agent. | 07-04-2013 |
20130177607 | Nanocell Drug Delivery System - Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent. | 07-11-2013 |
20140363497 | Nanocell Drug Delivery System - Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent. | 12-11-2014 |
20150099001 | Nanocell Drug Delivery System - Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent. | 04-09-2015 |
Patent application number | Description | Published |
20090149549 | PREPARATION OF CHIRAL AMIDES AND AMINES - This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure. | 06-11-2009 |
20120095106 | PREPARATION OF CHIRAL AMIDES AND AMINES - This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure. | 04-19-2012 |
20140057990 | PREPARATION OF CHIRAL AMIDES AND AMINES - This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure. | 02-27-2014 |
Patent application number | Description | Published |
20090175852 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS - In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions. | 07-09-2009 |
20100130465 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS - The present invention relates to novel Anilinopiperazine Derivatives of formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase. | 05-27-2010 |
20100145048 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - This invention relates to compounds of the Formula (I): | 06-10-2010 |
20100179141 | NOVEL JNK INHIBITORS - Disclosed are compounds of the formula (I) wherein X is N or CH, and Y is N or CR | 07-15-2010 |
20100286135 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS - The present invention relates to novel heterocyclic amide compounds of Formula I: as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are compositions comprising said compounds, and methods for using said compounds for treating or preventing a proliferative disease, an anti-proliferative disorder, inflammation, arthritis, a neurological or neurodegenerative disease, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease or a fungal disease. | 11-11-2010 |
20100298314 | NOVEL JNK INHIBITORS - Disclosed are substituted imidazo[1,2-a]pyridines, imidazo[1,2-a]pyrazines, imidazo[1,2-c]pyrimidines and imidazo[1,2-d]triazines compounds of the formula: (1.0) Also disclosed are methods for treating JNK1 and ERK mediated diseases using the compounds of formula 1.0. | 11-25-2010 |
20100331313 | Thiazole Derivatives as Protein Kinase Inhibitors - The present invention relates to novel Thiazole Derivatives, compositions comprising the Thiazole Derivatives, and methods for using the Thiazole Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral infection, a fungal infection, or a disorder related to the activity of a protein kinase. | 12-30-2010 |
Patent application number | Description | Published |
20090245253 | Computing Point-to-Multipoint Paths - An apparatus comprising a path computation element (PCE) configured to communicate with a path computation client (PCC) and compute a point-to-multipoint (P2MP) path across an autonomous system (AS) domain. Also included is a network component comprising at least one processor configured to implement a method comprising obtaining a computation request for a P2MP path across a plurality of AS domains, attempting to calculate the P2MP path across the AS domains, thereby generating a computed path or a failure reason, and transmitting a reply comprising the computed path or an indication of the failure reason. Included is a method comprising exchanging a request message and a reply message about a P2MP path across an AS domain between a PCC and a PCE. | 10-01-2009 |
20090252058 | Multi-Protocol Label Switching Multi-Topology Support - A network component comprising at least one processor configured to implement a method comprising receiving a packet, determining whether the packet comprises a topology label, and adding the topology label to the packet if the packet does not comprise the topology label. Included is a method comprising routing a plurality of packets corresponding to a plurality of forwarding equivalence classes (FECs) over a plurality of network topologies using a topology label and plurality of forwarding labels for each network topology. Also included is a network comprising a plurality of nodes in communication with each other and having a plurality of network topologies, wherein at least some of the nodes are configured to route data packets for a plurality of FECs along a path in each network topology using a topology label corresponding to each network topology and an inner label corresponding to each FEC. | 10-08-2009 |
20090303904 | System and Method for Multi-Topology Support - A system and method for providing multi-topology support in RSVP-TE in a multi-protocol label switching network is provided. A method includes reserving path states for a traffic engineered label switched path (TE LSP), and releasing the reserved path states. The TE LSP is established within a single network topology in an environment of multiple network topologies, and the reserving path states includes sending a first resource reservation protocol with traffic engineering (RSVP-TE) message containing multi-topology information. | 12-10-2009 |
20100177631 | Protecting Ingress and Egress of a Label Switched Path - An apparatus comprising a backup node coupled to an ingress node of a point-to-multipoint (P2MP) label switched path (LSP) and to a plurality of next-hop nodes of the ingress node of the P2MP LSP via a backup tree, wherein the backup node and the ingress node are both coupled to an external node, and wherein the backup node is configured to ensure data delivery in the P2MP LSP when the ingress node fails. Included is a network component comprising at least one processor configured to implement a method comprising detecting a failure in an ingress node of a P2MP LSP, receiving a data packet destined for the ingress node and to be transported by the P2MP LSP from a provider node when the ingress node fails, and transmitting the data packet on a backup tree that merges with the P2MP LSP prior to reaching an egress node. | 07-15-2010 |
20100208733 | System and Method for Point to Multipoint Inter-Domain Multiprotocol Label Switching Traffic Engineering Path Calculation - A system comprising a plurality of path computation elements (PCEs) configured to communicate with an ingress node, jointly compute a core tree for an inter-domain point-to-multipoint (P2MP) tree across a plurality of network domains, and independently compute a plurality of sub-trees in at least some of the network domains, wherein the core tree connects the ingress node to a boundary node (BN) in each one of the network domains that have a destination node and each sub-tree connects the BN to a plurality of destination nodes in one of the network domains that have a destination node. | 08-19-2010 |
20110235503 | System and Method for Communications System Routing Component Level High Availability - A system and method for communications system routing component level high availability are provided. A method for providing routing component level high availability includes synchronizing information from an active information source, detecting a failure in a routing component, replacing the failed routing component with a backup routing component, and completing synchronization of the information. | 09-29-2011 |
20120057593 | Computing Point-to-Multipoint Paths - An apparatus comprising a path computation element (PCE) configured to communicate with a path computation client (PCC) and compute a point-to-multipoint (P2MP) path across an autonomous system (AS) domain. Also included is a network component comprising at least one processor configured to implement a method comprising obtaining a computation request for a P2MP path across a plurality of AS domains, attempting to calculate the P2MP path across the AS domains, thereby generating a computed path or a failure reason, and transmitting a reply comprising the computed path or an indication of the failure reason. Included is a method comprising exchanging a request message and a reply message about a P2MP path across an AS domain between a PCC and a PCE. | 03-08-2012 |
20120250583 | Multi-Protocol Label Switching Multi-Topology Support - A network component comprising at least one processor configured to implement a method comprising receiving a packet, determining whether the packet comprises a topology label, and adding the topology label to the packet if the packet does not comprise the topology label. Included is a method comprising routing a plurality of packets corresponding to a plurality of forwarding equivalence classes (FECs) over a plurality of network topologies using a topology label and plurality of forwarding labels for each network topology. Also included is a network comprising a plurality of nodes in communication with each other and having a plurality of network topologies, wherein at least some of the nodes are configured to route data packets for a plurality of FECs along a path in each network topology using a topology label corresponding to each network topology and an inner label corresponding to each FEC. | 10-04-2012 |
20130088953 | Failure Detection in the Multiprotocol Label Switching Multicast Label Switched Path's End-to-End Protection Solution - In one aspect, the invention includes, in a root node along a secondary label switching path, a computer program product comprising computer executable instructions stored on a non-transitory medium that when executed by a processor cause the root node to perform the following: establish a first data plane based failure detection session having an inactive status along a first label switching path (LSP) with at least one leaf node, receive a predetermined number of notification messages from the leaf node, wherein the predetermined number of notification messages indicate the failure of a second data plane based failure detection session along a second LSP from a second processor to the leaf node, and change the status of the first data plane based failure detection session to active along the first LSP upon receipt of the predetermined number of notification messages. | 04-11-2013 |
20130089100 | Point-To-Point Based Multicast Label Distribution Protocol Local Protection Solution - In one aspect, the disclosure includes an apparatus comprising a processor configured to receive node protection backup route data at an upstream node and determine at least one backup route to at least one merge point node of a protected link or node according to the node protection data. In another aspect, the disclosure includes an apparatus comprising a processor configured to: receive at an upstream component information from a downstream component, wherein the received information comprises one or more of the following data elements related to one or more merge point nodes of a protected node: a number of leaf nodes, a plurality of merge point node addresses, a plurality of merge point node label reserve times and a plurality of merge point node forwarding labels, and establish a backup tunnel at the upstream component using at least one of the data elements received from the downstream component. | 04-11-2013 |
20130100953 | In Band Signaling in Next Generation-Multicast Virtual Private Network Using Receiver Driven Resource Reservation Protocol-Traffic Engineering Point-To-Multipoint - A method executed by a processor in a network node positioned inside a Multiprotocol Label Switching (MPLS) core network for establishing a Point to Multipoint (P2MP) Virtual Private Network (MVPN), comprising receiving a Protocol-Independent Multicast (PIM) Join message from a node outside the MPLS core network, wherein the PIM Join message comprises a source VPN identifier (ID) and propagating the source VPN ID across a P2MP Label Switched Path (LSP) established in the MPLS core network with in-band signaling using Resource Reservation Protocol-Traffic Engineering (RSVP-TE). | 04-25-2013 |
20130121169 | Point to Multi-Point Based Multicast Label Distribution Protocol Local Protection Solution - In one aspect, the disclosure includes an apparatus comprising a processor configured to function as a merge point (MP) in a point to multi-point (P2MP) backup label switching path (LSP) for a primary LSP, receive P2MP backup LSP information originating from a protected node, wherein the P2MP backup LSP information comprises the identity of a point of local repair (PLR), determine a backup label switching router (LSR), and send a message with the identity of the backup LSR to an upstream node. | 05-16-2013 |
20130250963 | RSVP-TE MP2MP Solution - An apparatus comprising a processor configured to store a first upstream label in a forwarding table upon receipt of a first message encapsulating the first upstream label from a first adjacent node, store a first downstream label in the forwarding table upon receipt of a second message encapsulating the first downstream label from a second adjacent node, send a third message encapsulating a second downstream label to the first adjacent node, send a fourth message encapsulating a second upstream label to the second adjacent node; and forward data received from a plurality of adjacent nodes over a MP2MP LSP using at least a portion of the labels stored in the forwarding table, wherein each adjacent node is associated with only one upstream label and only one downstream label, and wherein the maximum state complexity of the forwarding table is linear relative to the number of adjacent nodes. | 09-26-2013 |
20130294455 | Automatic Method for Setting Up mLDP LSP Through P2P Tunnel - An apparatus comprising a processor configured to send a first notification message to a first label switch router (LSR) to discover the upstream multipoint Label Distribution Protocol (mLDP) LSR, wherein the apparatus is configured to couple to the first LSR, and wherein the first LSR is not an mLDP LSR, receive a second notification message from the upstream mLDP node, and in response to receiving the second notification message, establish an mLDP Label Switch Path (LSP) to the upstream mLDP node via the first LSR. | 11-07-2013 |
20130336191 | mRSVP-TE Based Fast Reroute in Detour (1:1) Protection Mode - An apparatus comprising a memory, and a processor coupled to the memory and configured to transmit a multicast Resource Reservation Protocol—Traffic Engineering (mRSVP-TE) path request (PATH) message upstream, wherein the PATH message requests reservation of a backup Label Switched Path (LSP) to protect an active LSP configured to transmit multicast data. The disclosure also includes a computer program product comprising computer executable instructions stored on a non-transitory computer readable medium such that when executed by a processor cause a network element (NE) to receive a multicast PATH message from a downstream node, wherein the NE acts as a Point of Local Repair (PLR) along an active LSP, wherein the active LSP is configured to transmit multicast data, and wherein the PATH message requests reservation of a backup LSP to protect the active LSP. | 12-19-2013 |
20130336192 | mRSVP-TE Based Fast Reroute in Facility (1:N) Protection Mode - An apparatus comprising a memory, and a processor coupled to the memory and configured to transmit a backup Label Switched Path (LSP) multicast Resource Reservation Protocol-Traffic Engineering (mRSVP-TE) path request (PATH) message upstream, wherein the backup LSP PATH message requests reservation of a first backup LSP to protect a first primary LSP configured to transmit multicast data, and wherein the backup LSP PATH message is transmitted to support a facility mode one to many ( | 12-19-2013 |
20140119367 | Encoding Packets for Transport Over SDN Networks - An ingress node in a Software Defined Network (SDN) comprising a receiver for receiving a data packet, a processor coupled to the receiver and further configured to obtain the data packet from the receiver in a transport protocol agnostic manner, and encapsulate the data packet in an SDN packet header, wherein the packet header comprises SDN flow-specific information provided by an SDN controller, and a transmitter coupled to the processor and further configured to transmit the encapsulated data packet across a single SDN toward an egress node in the SDN. | 05-01-2014 |
20140122683 | System and Method for Virtual Network Abstraction and Switching - Embodiments are provided herein to enable single level network abstraction for a service across one or more domains. The embodiments use a single network ID to identify a service and a corresponding virtual network topology across any number of domains at a physical network. A virtual network topology can be abstracted for each service, based on the physical underlying network topology. A network controller determines, for a service, the virtual network topology within a physical network, and binds the service to the virtual network topology via a virtual network ID, which defines a single forwarding domain of the virtual network topology across the physical network. The virtual network ID is then indicated to the nodes of the virtual network topology, thus enabling the nodes to identify and forward traffic for the service, within the single forwarding domain, between end clients from edge to edge of the physical network. | 05-01-2014 |
20140160987 | Enhanced Upstream Label Assignment (ULA) Mechanism For Point To Multi-Point (P2MP) and/or Multi-Point To Multi-Point (MP2MP) Facility Protection - A computer program product comprising computer executable instructions stored on a non-transitory medium of an upstream node in a network system comprising a plurality of nodes that when executed by a processor cause the node to advertise an upstream assigned label to a downstream node, receive a message from the downstream node, and if the received message confirms that no conflict with the upstream assigned label exists at the downstream node, assign the upstream-assigned label, or if the received message confirms that a conflict with the upstream-assigned label exists at the downstream node, either select a new upstream-assigned label or wait until indication is received that the label resource has become available. | 06-12-2014 |
20140161124 | Enhanced Upstream Label Assignment (ULA) Mechanism For Point To Multi-Point (P2MP) and/or Multi-Point To Multi-Point (MP2MP) Facility Protection - A computer program product comprising computer executable instructions stored on a non-transitory medium of an upstream node in a network system comprising a plurality of nodes that when executed by a processor cause the node to advertise an upstream assigned label to a downstream node, receive a message from the downstream node, and if the received message confirms that no conflict with the upstream assigned label exists at the downstream node, assign the upstream-assigned label, or if the received message confirms that a conflict with the upstream-assigned label exists at the downstream node, either select a new upstream-assigned label or wait until indication is received that the label resource has become available. | 06-12-2014 |
20150103844 | Using PCE as SDN Controller - Embodiments relate generally to systems and methods for transitioning a system from a tradition network to a Software Defined Network (SDN) enabled network. In some embodiments, the systems and methods may comprise the use of a Path Computation Element (PCE) as a central controller. Smooth transition between traditional network and the new SDN enabled network, especially from a cost impact assessment perspective, may be accomplished using the existing PCE components from the current network to function as the central controller of the SDN network is one choice, which not only achieves the goal of having a centralized controller to provide the functionalities needed for the central controller, but also leverages the existing PCE network components. | 04-16-2015 |
Patent application number | Description | Published |
20090028821 | PRODRUGS OF CC-A1065 ANALOGS - The present invention provides prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group containing a sulfonic acid containing phenyl carbamate, in which the protecting group confers enhanced water solubility upon the prodrug, and in which the prodrug also has a moiety, such as a sulfide or a disulfide, that can conjugate to a cell binding reagent such as an antibody, and for the therapeutic use of such prodrug and conjugates, and for processes for preparing such prodrugs and conjugates. | 01-29-2009 |
20090036431 | Cytotoxic Agents Comprising New Tomaymycin Derivatives - The present invention is related to new tomaymycin derivatives, their process of preparation and their therapeutic uses. | 02-05-2009 |
20100203007 | NOVEL BENZODIAZEPINE DERIVATIVES - The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 08-12-2010 |
20110280890 | PRODRUGS OF CC-1065 ANALOGS - The present invention provides prodrugs of analogs of the anti-tumor antibiotic CC-1065 having a cleavable protective group containing a sulfonic acid containing phenyl carbamate, in which the protecting group confers enhanced water solubility upon the prodrug, and in which the prodrug also has a moiety, such as a sulfide or a disulfide, that can conjugate to a cell binding reagent such as an antibody, and for the therapeutic use of such prodrug and conjugates, and for processes for preparing such prodrugs and conjugates. | 11-17-2011 |
Patent application number | Description | Published |
20090274713 | CROSS-LINKERS AND THEIR USES - Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same. | 11-05-2009 |
20120165537 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS - Processes for the preparation of charged crosslinkers bearing a sulfonic acid moiety are disclosed. These procedures also optionally include methods to convert the resulting products to substantially a single salt form. | 06-28-2012 |
20130011419 | CROSS-LINKERS AND THEIR USES - Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same. | 01-10-2013 |
20130266596 | NOVEL BENZODIAZEPINE DERIVATIVES - The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 10-10-2013 |
20130302357 | NOVEL BENZODIAZEPINE DERIVATIVES - The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 11-14-2013 |
20140135502 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS - Processes for the preparation of charged crosslinkers bearing a sulfonic acid moiety are disclosed. These procedures also optionally include methods to convert the resulting products to substantially a single salt form. | 05-15-2014 |
20140142297 | METHODS FOR THE ACYLATION OF MAYTANSINOL - Disclosed is a method of preparing an amino acid ester of maytansinol by reacting maytansinol with an N-carboxyanhydride of an amino acid (NCA) in the presence of a drying agent. Also disclosed is an improved method of preparing an amino acid ester of maytansinol in which a nucleophile is added to the reaction mixture after completion of the reaction between maytansinol and an N-carboxyanhydride of an amino acid. | 05-22-2014 |
20140178416 | CROSS-LINKERS AND THEIR USES - Charged or pro-charged cross-linking moieties and conjugates of cell binding agents and drugs comprising the charged or pro-charged cross-linking moieties and method of making the same. | 06-26-2014 |
20150030616 | NOVEL BENZODIAZEPINE DERIVATIVES - The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 01-29-2015 |
20150191488 | METHODS FOR THE ACYLATION OF MAYTANSINOL - Disclosed is a method of preparing an amino acid ester of maytansinol by reacting maytansinol with an N-carboxyanhydride of an amino acid (NCA) in the presence of a drying agent. Also disclosed is an improved method of preparing an amino acid ester of maytansinol in which a nucleophile is added to the reaction mixture after completion of the reaction between maytansinol and an N-carboxyanhydride of an amino acid. | 07-09-2015 |
20150284416 | NOVEL LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES - Cell binding agent-drug conjugates comprising hydrophilic linkers, and methods of using such linkers and conjugates are provided. | 10-08-2015 |
20150314017 | DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL-BINDING MOLECULE - The present invention relates to novel disulfur bridge linkers containing hydrazine used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking a pair of thiols on the cell-binding molecule. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders. | 11-05-2015 |
20150322155 | ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE - The present invention relates to novel acetylenedicarboxyl linkers used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking pairs of thiols on the cell-binding molecule. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders. | 11-12-2015 |
Patent application number | Description | Published |
20100049740 | WORKFLOW TEMPLATE MANAGEMENT FOR MEDICAL IMAGE DATA PROCESSING - Some embodiments of a workflow management system to process medical image data generated by a medical imaging device have been presented. In one embodiment, a user selects a workflow template with a predefined set of image processing stages, and applies the workflow template to the medical image data. Each of the predefined set of image processing stages in the workflow template includes one or more image processing operations. Each of the image processing operations is capable of generating metadata for processing the medical image data. The medical image data is then processed through each of the predefined image processing stages. The result of processing is a collection of metadata. Each metadata in the collection can be applied to the medical image data to generate a medical image view. | 02-25-2010 |
20130124459 | WORKFLOW TEMPLATE MANAGEMENT FOR MEDICAL IMAGE DATA PROCESSING - According to one embodiment, workflow templates are stored, each including a predefined sequence of workflow stages associated with a particular type of medical diagnosis or process. Each workflow stage defines one or more image processing operations to be performed. At least one workflow stage generates metadata specifying a parameter to be used by another workflow stage for processing a corresponding medical image. In response to medical image data received, at least one of the image processing operations defined by the workflow stages is performed on the medical image data. A scene is generated for each of the workflow stages representing an image view representing the medical image data. In response to a save or validate command received from a user, the scene associated with each of the workflow stages is stored in a persistent storage, which can be used to recreate a corresponding medical image view subsequently. | 05-16-2013 |
20130208955 | CLOUD-BASED MEDICAL IMAGE PROCESSING SYSTEM WITH ACCESS CONTROL - According to one embodiment, a cloud server receives over a network a request for accessing three-dimensional (3D) medical image data from a first user, where the cloud server provides image processing services to a plurality of users using a plurality of image processing tools provided by the cloud server. The cloud server determines user privileges of the users for accessing the 3D medical image data, where the user privileges are related to the 3D medical image data. The 3D medical image data was captured by a medical imaging device and stored in a storage associated with the cloud server. The availability of the image processing tools is limited to the user to process the 3D medical image data based on the user privileges. | 08-15-2013 |
20130208966 | CLOUD-BASED MEDICAL IMAGE PROCESSING SYSTEM WITH ANONYMOUS DATA UPLOAD AND DOWNLOAD - According to one embodiment, a local device receives 3D medical image data captured by a medical imaging device. The 3D medical image is anonymized by removing certain metadata associated with the 3D medical image data based on an anonymization template. The local device automatically uploads the anonymized 3D medical image data to a cloud server over a network based on a set of one or more rules, using a network connection established via an internet port of the local device. The cloud server is configured to provide medical image processing services to a plurality of users using a plurality of image processing tools provided by the cloud server. | 08-15-2013 |
20130308839 | INTEGRATION OF MEDICAL SOFTWARE AND ADVANCED IMAGE PROCESSING - According to one embodiment, at least a portion of medical information of a patient is displayed within MRCS executed within a local device, the medical information including medical treatment history of the patient. At least a portion of the displayed medical information of the patient is transmitted to a medical imaging processing server over a network, where the transmitted medical information includes a patient identifier (ID) of the patient. Both the at least a portion of patient medical information and one or more medical images are displayed within the MRCS, where the medical images are associated with the patient and rendered by the medical image processing server. A set of icons representing a set of image processing tools is displayed within the MRCS, which when activated by a user, allow an image to be manipulated by the imaging processing server. | 11-21-2013 |
20140153808 | CLOUD-BASED MEDICAL IMAGE PROCESSING SYSTEM WITH TRACKING CAPABILITY - A cloud server receives a request for accessing medical image data from a client device, where the cloud server provides image processing services to users in image processing steps, resulting in image views. User privileges of a user are determined for accessing the medical image data. In response to receiving a command having a selection of an image view from the client device, the cloud server provides the medical image data based on the selected one or more image views. The user interactions of the user with the medical image data via the selected image views are tracked, including tracking how long in time the user has spent on a particular image view. The tracked user interactions are stored in a persistent storage, and an analysis is performed on the tracked user interactions stored in the persistent storage to determine an overall usage trend of the image views. | 06-05-2014 |
20150055838 | INTEGRATION OF MEDICAL SOFTWARE AND ADVANCED IMAGE PROCESSING - According to one embodiment, at least a portion of medical information of a patient is displayed within MRCS executed within a local device, the medical information including medical treatment history of the patient. At least a portion of the displayed medical information of the patient is transmitted to a medical imaging processing server over a network, where the transmitted medical information includes a patient identifier (ID) of the patient. Both the at least a portion of patient medical information and one or more medical images are displayed within the MRCS, where the medical images are associated with the patient and rendered by the medical image processing server. A set of icons representing a set of image processing tools is displayed within the MRCS, which when activated by a user, allow an image to be manipulated by the imaging processing server. | 02-26-2015 |
20150089365 | ADVANCED MEDICAL IMAGE PROCESSING WIZARD - An automatic medical image processing system includes a series of operation stages, each automating specifying the image processing parameters for processing medical images. In response to an image processing indicator, a first medical image is automatically identified, including determining a first image operation and image processing parameters, without user intervention. The first image operation is performed on the first medical image based on the image processing parameters. A second medical image is generated and transmitted to the client device to be presented therein. The client device displays a message prompting the user whether the user is satisfied with the second medical image. In response to a user input from the client device indicating that the user is unsatisfied with the second medical image, one or more remedial options are presented to allow the user selecting a remedial action to reprocess the first medical image. | 03-26-2015 |
Patent application number | Description | Published |
20090259446 | Method to generate numerical pseudocores using borehole images, digital rock samples, and multi-point statistics - Methods and systems for creating a numerical pseudocore model, comprising: a) obtaining logging data from a reservoir having depth-defined intervals of the reservoir, and processing the logging data into interpretable borehole image data having unidentified borehole image data; b) examining one of the interpretable borehole image data, other processed logging data or both to generate the unidentified borehole image data, processing the generated unidentified borehole image data into the interpretable borehole image data to generate warped fullbore image data; c) collecting one of a core from the reservoir, the logging data or both and generating a digital core data from one of the collected core, the logging data or both such that generated digital core data represents features of one or more depth-defined interval of the reservoir; and d) processing generated digital core data, interpretable borehole image data or the logging data to generate realizations of the numerical pseudocore model. | 10-15-2009 |
20110004447 | Method to build 3D digital models of porous media using transmitted laser scanning confocal mircoscopy and multi-point statistics - Methods for characterizing a three-dimensional (3D) sample of porous media using at least one measuring tool that retrieves two or more set of transmitted measured data at two or more depths of the sample, such that the retrieved two or more set of transmitted measured data is communicated to a processor and computed in at least one multi-point statistical (MPS) model. | 01-06-2011 |
20120275658 | PETROGRAPHIC IMAGE ANALYSIS FOR DETERMINING CAPILLARY PRESSURE IN POROUS MEDIA - This disclosed subject matter is generally related to methods for characterizing two-dimensional (2D) and three-dimensional (3D) samples to determine pore-body and pore-throat size distributions and capillary pressure curves in porous media using petrographic image analysis. Input includes high-resolution petrographic images and laboratory-derived porosity measurements. Output includes: (1) pore-body and pore-throat size distributions, and (2) simulated capillary pressure curves for both pore bodies and pore throats. | 11-01-2012 |
20120277996 | METHOD TO DETERMINE REPRESENTATIVE ELEMENT AREAS AND VOLUMES IN POROUS MEDIA - The subject disclosure relates to methods for determining representative element areas and volumes in porous media. Representative element area (REA) is the smallest area that can be modeled to yield consistent results, within acceptable limits of variance of the modeled property. Porosity and permeability are examples of such properties. In 3D, the appropriate term is representative element volume (REV). REV is the smallest volume of a porous media that is representative of the measured parameter. | 11-01-2012 |
20120281883 | METHODS TO BUILD 3D DIGITAL MODELS OF POROUS MEDIA USING A COMBINATION OF HIGH- AND LOW-RESOLUTION DATA AND MULTI-POINT STATISTICS - This subject disclosure describes methods to build and/or enhance 3D digital models of porous media by combining high- and low-resolution data to capture large and small pores in single models. High-resolution data includes laser scanning fluorescence microscopy (LSFM), nano computed tomography (CT) scans, and focused ion beam-scanning electron microscopy (FIB-SEM). Low-resolution data includes conventional CT scans, micro computed tomography scans, and synchrotron computed tomography scans. | 11-08-2012 |
20140212006 | METHOD FOR QUANTITATIVE PREDICTION OF MATRIX ACIDIZING TREATMENT OUTCOMES - In one embodiment, the current application discloses a method comprising: performing a computed tomography (CT) porosity scan on a core sample, the core sample comprising a portion of a formation of interest; in response to the CT porosity scan, interpreting a porosity profile of the core sample; and in response to the porosity profile, modeling a response of a formation of interest to a predetermined treatment to determine a reacted formation configuration, wherein the predetermined treatment comprises an acid fluid treatment schedule, and wherein the modeling further comprises modeling acid fluid flow through the formation of interest having the porosity profile, and wherein the modeling further comprises accounting for acid reaction products during the predetermined treatment and shut-in period. | 07-31-2014 |
Patent application number | Description | Published |
20080286781 | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer - The invention relates to nucleic acid molecules and proteins associated with cervical cancer including pre-malignant conditions such as dysplasia. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers are also provided. | 11-20-2008 |
20080311573 | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer - The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided. | 12-18-2008 |
20100075325 | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER - The invention relates to nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided. | 03-25-2010 |
20100105051 | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided. | 04-29-2010 |
20100291068 | NUCLEIC ACID MOLECULES AND PROTEINS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF OVARIAN CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided. | 11-18-2010 |
20100291616 | NOVEL GENES, COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CERVICAL CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with cervical cancer including pre-malignant conditions such as dysplasia. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers are provided. | 11-18-2010 |
20110092388 | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided. | 04-21-2011 |
20120064548 | NOVEL GENES, COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CERVICAL CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with cervical cancer including pre-malignant conditions such as dysplasia. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers are provided. | 03-15-2012 |
20120264625 | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF CERVICAL CANCER - The invention relates to nucleic acid molecules and proteins associated with cervical cancer including pre-malignant conditions such as dysplasia. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers are also provided. | 10-18-2012 |
Patent application number | Description | Published |
20080234346 | PYRAZALIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS - The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin EP2 and/or EP4 receptors. | 09-25-2008 |
20080287474 | Antiproliferative Pyrimidyl, Fused Pyrimidyl and Pyrimidyl Hydrazones - The present invention is related to a novel series of pyrimidyl or fused pyrimidyl hydrazones. Compounds of Formula (I) wherein A is selected from the group consisting of Formulas (A1), (A2), (A3), (A4), (A5) are useful for the treatment and/or prevention of a proliferative disease. | 11-20-2008 |
20090292000 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS - Substituted pyrrolidine compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteoporosis and other destructive bone disease or disorder, and other diseases and disorders associated with the prostaglandin family of compounds. In a preferred aspect, a substituted pyrrolidine compound is administered to a subject in coordination with a phosphodiesterase inhibitor compound. | 11-26-2009 |
20120238575 | ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES - The present invention is related to a novel series of pyrimidyl or fused pyrimidyl hydrazones. Compounds of Formula (I) wherein A is selected from the group consisting of Formulas (A1), (A2), (A3), (A4), (A5) are useful for the treatment and/or prevention of a proliferative disease. | 09-20-2012 |
20140255381 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer. | 09-11-2014 |
20140371460 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer. | 12-18-2014 |
20150210681 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS - The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer. | 07-30-2015 |